Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 360, Issue 2, 1999, Pages 109-115

  Bryan Lluka, Lesley J ^a   Siebert, Gerhard A ^a,b   Pond, Susan M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WOLSTON PARK HOSPITAL   (Australia)

Author keywords

5 HT transporter; Dopamine transporter; Haloperidol metabolites; Haloperidol toxicity; K(i) values; MPP+; Noradrenaline transporter; Uptake inhibition

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3 DIHYDRO 1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE TRANSPORTER; DRUG METABOLITE; HALOPERIDOL; NEUROTOXIN; NORADRENALIN; SEROTONIN TRANSPORTER;

ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROTOXICITY; NONHUMAN; TARDIVE DYSKINESIA;

ANIMALS; ANTI-DYSKINESIA AGENTS; BIOGENIC MONOAMINES; BIOLOGICAL TRANSPORT, ACTIVE; CERCOPITHECUS AETHIOPS; COS CELLS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; NOREPINEPHRINE; SEROTONIN; TRANSFECTION;

EID: 0032823774     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002109900060     Document Type: Article

References (29)

1. Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16 : 73-93
2. Avent KM, Usuki E, Eyles DW, Keeve R, Van der Schyf CJ, Castagnoli N, Pond SM (1996) Haloperidol and its tetrahydropyridine derivative (HPTP) are metabolized to potentially neurotoxic pyridinium species in the baboon. Life Sci 59 : 1473-1482
3. Avent KM, Riker RR, Fraser GL, Van der Schyf CJ, Usuki E, Pond SM (1997) Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate? Life Sci 61 : 2383-2390
4. Benes FM, Paskevich PA, Davidson J, Domesick VB (1985a) The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res 329 : 265-273
5. Benes FM, Paskevich PA, Davidson J, Domesick VB (1985b) Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats. Brain Res 348 : 15-20
6. Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli N (1994) 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture und neurotransmitter uptake studies. J Pharmacol Exp Ther 270 : 822-830
7. Bryan-Lluka LJ, Siebert GA, Pond SM (1998) Metabolites of haloperidol inhibit the transporters for noradrenaline, dopaminc and serotonin. Naunyn-Schmiedeberg's Arch Pharmacol 358 [Suppl 1] : R28
8. Buck KJ, Amara SG (1994) Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA 91 : 12584-12588
9. 50) of an enzymatic reaction. Biochem Pharmacol 22 : 3099-3108
10. Christensen E, Moller JE, Faurbye A (1970) Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand 46 : 14-23
11. El-Sokby A (1986) Site of action of antischizophrenics. In: Winslow W, Markstein R (eds) The neurobiology of dopamine systems. Manchester University Press, New York, pp 240-251
12. Eyles DW, Avent KM, Stedman TJ, Pond SM (1997) Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci 60 : 529-534
13. Fang J, Yu PH (1995) Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices. Psychopharmacology 121 : 379-384
14. +) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology 121 : 373-378
15. Gerlach J, Casey D (1988) Tardive dyskinesia. Acta Psychiatr Scand 77 : 369-378
16. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82 : 2173-2177
17. Jeste DV, Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19 : 303-315
18. Lowry O, Rosebrough N, Farr A, Randall R (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193 : 265-275
19. Meshul CK, Casey DE (1989) Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res 489 : 338-346
20. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36 : 2503-2508
21. Pifl C, Hornykiewicz O, Giros B, Caron MG (1996) Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. J Pharmacol Exp Ther 277 : 1437-1443
22. Ramsay RR, Dadgar J, Trevor A, Singer TP (1986) Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci 39 : 581-588
23. Siebert GA, Bryan-Lluka LJ, Pond SM (1997) Haloperidol metabolites are inhibitors of the noradrenaline transporter. Proc Aust Soc Clin Exp Pharmacol Toxicol 4 : 116
24. Subramanyam B, Rollema H, Woolf T, Castagnoli N (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166 : 238-244
25. Subramanyam B, Pond SM, Eyles DW, Whiteford HA, Fouda HG, Castagnoli N (1991a) Identification of a potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem Biophys Res Commun 181 : 573-578
26. Subramanyam B, Woolf T, Castagnoli N (1991b) Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 4 : 123-128
27. Usuki E, Pearce R, Parkinson A, Castagnoli N (1996) Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem Res Toxicol 9 : 800-806
28. Van der Schyf CJ, Castagnoli K, Usuki E, Fouda HG, Rimoldi JM, Castagnoli N (1994) Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem Res Toxicol 7 : 281-285
29. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR (1998) Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788 : 215-222